ArticleNature communications2024
Thermal-responsive activation of engineered bacteria to trigger antitumor immunity post microwave ablation therapy.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Targeting Macrophage-Mediated Lymphatic Immunosuppression to Prevent Tumor Recurrence After Microwave Ablation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Programmable engineered bacteria manipulate metabolism and remodel the TME in situ for enhancing adoptive cell therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Programmable Encapsulation Enables On-Demand Proliferation of Therapeutic Bacteria for Potent Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Living Microbial Drugs.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- From tumor targeting to tumor accessibility: surface-engineered bacteria as precision living therapeutics for translational medicine.Journal of hematology & oncology · 2026Review
- Regulation of PD-1PD-L1 Immune Checkpoints by Gut Microbiota Metabolites and Their Clinical Translational Research: A Review.Immunity, inflammation and disease · 2026Review
- Microwave thermal supercharging therapy enables selective tumor ablation via low-power radio frequency-responsive nanotopographies.Bioactive materials · 2026Article
- Negative temperature coefficient metamaterial absorber for uniform microwave heating.Nature communications · 2026Article
- Microwave ablation synergizes with LPS to drive abscopal tumor regression associated with ferroptosis in HCC.iScience · 2026Article
- Engineered bacteria reprogram tumor microenvironmentActa pharmaceutica Sinica. B · 2026Article
- Amodiaquine Enhances Anti-Melanoma Efficacy of Attenuated Salmonella via Targeting Glutathione Reductase in Neutrophils.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Harnessing the immune system: future directions in cancer immunotherapy.Frontiers in immunology · 2026Review
- The landscape of gut microbiota in hepatocarcinogenesis: a comprehensive review of pathogenesis and therapeutic interventions.International journal of surgery (London, England) · 2026Review
- Engineered bacteria and bacteria-derived nanomaterials for cancer therapy: Mechanisms, designs and advances.Bioactive materials · 2026Review
- Enhanced magnetic thermal ablation combined with immunotherapy for hepatocellular carcinoma using engineering microspheres.Materials today. Bio · 2025Article
- A stable and antibiotic-free plasmid expression system foriScience · 2025Article
- STAT1 and mScientific reports · 2025Article
- Combating cancer immunotherapy resistance: a nano-medicine perspective.Cancer communications (London, England) · 2025Review
- Bimetallic Ca/Zn Nanoagonist Remould the Immunosuppressive Hepatocellular Carcinoma Microenvironment Following Incomplete Microwave Ablation via Pyroptosis and the STING Signaling Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Resynthesis of synthetic biology techniques: combining engineered bacteria with other antitumour therapies.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Incomplete tumor removal after microwave ablation (MWA), a widely used hyperthermia-based therapy, can result in tumor recurrence. Herein, attenuated Salmonella typhimurium VNP20009 is engineered to release interleukin-15&interleukin-15-receptor-alpha (IL-15&IL-15Rα) in response to mildly elevated temperature. Such 15&15R@VNP colonizes in tumors upon intravenous injection, and the expression of IL-15&IL-15Rα is triggered by MWA. Anti-tumor immune responses are elicited, efficiently suppressing tumor growth even after incomplete microwave ablation. We further design VNP20009 with thermal-responsive co-expression of both IL-15&IL-15Rα and soluble programmed cell death protein (sPD-1). Such sPD-1-15&15R@VNP can also reverse the functional suppression of immune cells driven by PD-1/PD-L1 axis, reinvigorating progenitor exhausted T cells, a critical subset of cytotoxic T lymphocytes responsive to immune checkpoint blockade. Such thermal-responsive engineered bacteria are thus a promising adjuvant therapy to potentiate tumor ablation therapies via effectively activating antitumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.